$-0.02
(Market cap
$14,139 Mln
Recently Viewed
Clear AllMarket cap
$14,139 Mln
Revenue (TTM)
$8,463 Mln
P/E Ratio
23.2
P/B Ratio
2.6
Div. Yield
2.4 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
10.8
Debt to Equity
0.6
Book Value
$12.1
EPS
$1.4
Face value
--
Shares outstanding
426,785,899
CFO
$8,639.00 Mln
EBITDA
$12,623.00 Mln
Net Profit
$5,183.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Smith & Nephew SNATS - ADR
| 0.0 | 2.8 | 0.1 | 27.7 | 1.0 | -4.3 | -0.2 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Smith & Nephew SNATS - ADR
| 33.5 | -9.8 | 1.5 | -22.3 | -16.2 | -10.4 | 30.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Smith & Nephew SNATS - ADR
|
32.8 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
| 8.4 | 5,633.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 277.0 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 39.5 | 6,195.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.4 | |
| 27.3 | 4,414.8 | 2,719.5 | 47.0 | 8.4 | 1.6 | 96.2 | 1.4 | |
| 121.6 | 6,939.8 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.6 | |
| 81.9 | 5,456.9 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.6 | 5.0 | |
| 178.4 | 9,341.0 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 333.0 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 | |
| 129.2 | 7,400.2 | 738.3 | 48.9 | 11.4 | 2.4 | 150.8 | 3.5 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports... Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Read more
CEO & Director
Dr. Deepak S. Nath Ph.D.
CEO & Director
Dr. Deepak S. Nath Ph.D.
Headquarters
Watford
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Smith & Nephew SNATS Inc - ADR is $32.82 (NYSE) as of 22-Apr-2026 11:47 EDT. Smith & Nephew SNATS Inc - ADR has given a return of 0.95% in the last 3 years.
The P/E ratio of Smith & Nephew SNATS Inc - ADR is 23.17 times as on 10-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.86
|
2.71
|
|
2024
|
26.24
|
2.05
|
|
2023
|
90.54
|
4.56
|
|
2022
|
104.88
|
4.45
|
|
2021
|
58.00
|
5.46
|
The 52-week high and low of Smith & Nephew SNATS Inc - ADR are Rs 38.79 and Rs 26.02 as of 22-Apr-2026.
Smith & Nephew SNATS Inc - ADR has a market capitalisation of $ 14,139 Mln as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Smith & Nephew SNATS Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.